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Left bundle branch block (LBBB)are used to assess the risk for late atrioventricular block. However, the time of ECG evaluation remains controver-
sial. We aimed to compare the time course and dynamics of new onset ECG changes according to valve design in
balloon- (BEV) and self-expandable (SEV) TAVR.Background:New onset electrocardiographic (ECG) changes after transcatheter aortic valve replacement (TAVR)
Methods and results: This single center study enrolled 133 consecutive TAVR patients (28.6% SEV, 71.4% BEV). Pa-
tients with pre-existent permanent pacemaker implant (PPMI), procedural death or incomplete ECG registration
were excluded. Standard 12‑lead ECGwas performed before the procedure, at 1, 24, 48 and 120 h and 1month. In
BEV patients, no significant PR prolongation occurred, whereas in SEV patients the PR interval prolonged signif-
icantly with 33.7 ± 22.0 ms (p b 0.001, compared to pre-TAVR) but only after 48 h after TAVR. Widening of QRS
duration was comparable among both BEV and SEV patients (6.7 ± 21.5 versus 17.0 ± 26.9 ms, p=0.061) and
occurred immediately after TAVR. New-onset left bundle branch blockwas seen in 18.5% of BEV and 30.8% of SEV
patients (p = 0.120) and occurred within 24 h after TAVR in both groups. Late PPMI (N24 h after TAVR) was
higher in SEV compared to BEV patients (15.3% versus 1.5%, p= 0.008).
Conclusion: Self-expandable valves cause more impairment in atrioventricular conduction with a delayed time
course compared to balloon expandable valves. This might explain the higher pacemaker need beyond 24 h
after TAVR. Our findings suggest that patients with self-expandable valves require at least 48 h ECG monitoring
post TAVR.
© 2020 Published by Elsevier Inc.Introduction
Over the last decade, indications for transcatheter aortic valve re-
placement (TAVR) in symptomatic severe aortic stenosis have ex-
panded from extreme and high surgical risk patients towards
intermediate and more recently even to low surgical risk patients
[1–4]. Despite newer generation devices causing overall less complica-
tions, the occurrence of conduction disturbances remains the most fre-
quent complication after TAVR [5]. New-onset left bundle branch block
(LBBB) occurs in approximately 25% of patients and new permanentexpandable valves cause more
n-expandable valves.
, Ghent University Hospital, C.
an).
eliability and freedom from biaspacemaker implantation (PPMI) in approximately 15% of patients with
a substantially higher risk in patients treatedwith self-expanding valves
(SEV) compared to balloon expandable valves (BEV) [5,6].
The risk for post-procedural high grade atrioventricular block (AVB)
asserts heart rhythm monitoring and temporary pacing after TAVR. Al-
though themajority of conduction disturbances occur during or shortly
after the TAVR procedure, high degree AVBmay still occur after 48 h in 2
to 7% of patients [5,7]. Electrocardiographic (ECG) changes arising early
after TAVR might predict this risk of late AVB [7–10]. Several criteria
such as widening of QRS duration, occurrence of LBBB or PR interval
prolongation after TAVR are proposed to guide PPMI [5,7–10]. However,
the timing atwhich ECG changes should be evaluated differs among the
proposed strategies. Moreover, the time course of new onset ECG
changes according to the type of valve (SEV versus BEV) remains largely
uninvestigated.
The aim of our study was to assess and compare the dynamics of
new onset ECG and conduction changes after BEV and SEV TAVR. In
Table 1
Baseline demographic, procedural and ECG characteristics in patients with BEV and SEV
TAVR. BEV = balloon expandable valve; SEV = self expandable valve; BMI = body mass
index; BSA = body surface area; AHT = arterial hypertension; DM= diabetes mellitus;
CVA/TIA = cerebrovascular accident/transient ischemic attack; GFR = glomerular filtra-
tion rate; STSPROM = Society of Thoracic Surgeons Predicted Risk of Mortality; NYHA
class = New York Heart Association classification; NCC= non coronary cusp; LCC = left
coronary cusp; LBBB= left bundle branch block; RBBB= right bundle branch block; AVB
I = first degree atrioventricular block; LAHB = left anterior hemiblock; LPHB = left pos-
terior hemiblock.
BEV (n = 65) SEV (n = 26) P-value
Baseline patient characteristics
Age (y) 84.1 [81.4–87.5] 83.7 [81.6–86.5] 0.719
Female (%) 53.8 50.0 0.740
BMI (kg/m2) 26.5 ± 5.1 25.9 ± 4.1 0.620
AHT (%) 78.5 73.1 0.582
DM (%) 26.2 34.6 0.420
Ischaemic heart disease (%) 46.2 46.2 1.000
CVA/TIA (%) 18.5 11.5 0.421
GFR (ml/min) 43.4 ± 15.8 40.0 ± 14.0 0.755
Beta-blocker (%) 55.4 73.1 0.119
Calcium-blocker (%) 4.6 0.0 0.265
Amiodarone (%) 12.3 11.5 0.919
STSPROM 4.8 [3.4–7.2] 4.2 [3.5–7.2] 0.786
EuroSCORE II 5.9 [2.8–13.0] 8.3 [2.2–16.0] 0.432
NYHA class 0.273
NYHA I (%) 3.1 3.6
NYHA II (%) 32.3 31.1
NYHA III (%) 56.9 57.7
NYHA IV (%) 7.7 7.6
Procedural characteristics
Transfemoral access (%) 95.3 96.2 0.792
Diameter implanted valve (mm) 26.0 [23.0–26.0] 29.0 [26.0–29.0] b0.001
Predilation (%) 52.3 38.5 0.232
Depth of implantation at NCC (mm) 5.0 [4.0–7.0] 6.0 [5.0–8.0] 0.121
Depth of implantation at LCC (mm) 5.0 [4.0–7.0] 9.0 [7.0–11.0] b0.001
Baseline ECG characteristics
Sinus rhythm (%) 76.9 68.0 0.385
PR interval (ms) 188.8 ± 38.8 171.7 ± 30.4 0.114
QRS duration (ms) 112.2 ± 26.5 103.5 ± 26.5 0.067
LBBB (%) 18.5 16.0 0.784
RBBB (%) 4.6 4.1 0.899
AVB I (%) 34.0 22.2 0.354
LAHB (%) 9.7 11.3 0.793
LPHB (%) 1.5 0.0 0.965
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ics on ECG-based decision making for PPMI, duration of heart rhythm
monitoring and early discharge.
Methods
Study population
All consecutive patients undergoing TAVRwith the BEV Edwards Sa-
pienXTor Edwards Sapien 3 (Edwards Lifesciences, Irvine, CA, USA) and
SEVMedtronic EVOLUT R or EVOLUT PRO (Medtronic,Minneapolis,MN,
USA) at the University hospital of Ghent between January 2011 and Jan-
uary 2018were included in the study. All patients had symptomatic, se-
vere aortic stenosis and the indication for TAVR was established by the
multidisciplinary heart team. Patients with pre-existing pacemakers
(PM) or cardioverters-defibrillators (ICD), procedural death or incom-
plete ECG registration were excluded for further analysis. The study
was approved by the ethical committee of theGhentUniversity Hospital
(B670201838326) and informed consent was obtained from each pa-
tient in accordance with local ethical committee requirements. The
study complies with the declaration of Helsinki.
ECG analysis and measurements
Standard 12‑lead ECGs were recorded and analyzed at predefined
timings: baseline ECG pre TAVR procedure, 1 h, 24 h, 48 h, 120 h and
1 month after TAVR. All ECGs were recorded with MAC 5500 ECG re-
cording devices (GE Healthcare, Waukesha, WI, USA) and stored digi-
tally (aHL7 ECGs, sampling rates of 500 Hz) in a MUSE Cardiology
Information system (GE Healthcare). All ECGs were analyzed for
rhythm, conduction times and presence of atrioventricular or bundle
branch block. PR interval and QRS duration (QRSD) were measured au-
tomatically using the 12SL algorithm (GE Healthcare) as previously val-
idated in our center [11]. Delta (Δ) PR interval andΔQRS durationwere
calculated as difference between the PR interval and QRSD at the
predefined timings post TAVR and the baseline PR interval and QRSD.
Presence of atrioventricular and bundle branch block was evaluated
by two independent electrophysiologists blinded to the type of TAVR.
First-degree atrioventricular block (AVB I) was defined as a PR inter-
val ≥ 200 ms. Left bundle branch block (LBBB) was defined according
to the recent American Heart Association, American College of Cardiol-
ogy Foundation and Heart Rhythm Society criteria [12].
Procedure and pacemaker implantation
At the start of the TAVR procedure, all patients were implanted with
a temporary transjugular pacing electrode positioned in the apex of the
right ventricle. The temporary pacemaker was programmed to a ven-
tricular back up pacing mode (VVI 30 beats per minute) for 48 h post
TAVR. The need for PPMI was assessed at 48 h in agreement between
the treating physician and an electrophysiologist in compliance with
contemporary European Society of Cardiology guidelines on PPMI [13].
If no PPMI was scheduled at 48 h, the temporary pacing electrode was
removed.
Statistical methods
Quantitative data are presented as mean ± standard deviation
(SD) or median and interquartile range (IQR). The distribution of
quantitative variables was assessed for normality with histograms,
the Kolmogorov-Smirnov and the Shapiro-Wilk test. Quantitative
variables adjusting to a normal distribution were compared by Stu-
dent t-test, not normal distributed variables were compared with
the Mann-Whitney U test. Paired test were used for comparison
of PR interval and QRSD from each patient at different time inter-
vals (paired student t-test and Wilcoxon signed rank test).Categorical variables were expressed as counts and percentages
and compared by use of the Pearson Chi-Square or Fisher's Exact
test. All reported p values are 2 sided and p values b0.05 were con-
sidered statistically significant. Statistical analyses were per-
formed using IBM SPSS Statistics for Windows, Version 25.0 (IBM
Corp., Armonk, New York, USA).Results
Baseline patient characteristics
A total of 133 patients received TAVR: BEV n = 95 (71.4%) and
SEV n = 38 (28.6%). After exclusion of patients with a previously
implanted PM or ICD (n = 15), periprocedural death (n = 3) and
incomplete ECG registration (n = 24), 91 patients were available
for further analysis. Patient characteristics are summarized in
Table 1. There were no significant differences in baseline demo-
graphic and clinical patient characteristics between the BEV and
SEV. Besides a larger prosthesis size in the SEV, there were no sig-
nificant differences in procedural characteristics between both
groups. Valve implantation depth in SEV was lower when mea-
sured from the left coronary cusp but was comparable when
Table 2
Comparison of delta PR-interval and delta QRS duration vs baseline at different time inter-
vals between BEV and SEV. Comparison of proportion of new-onset LBBB at different time
intervals between BEV and SEV. BEV= balloon-expandable valve. SEV= self-expandable
valve.
BEV (n = 65) SEV (n = 26) P-value
Delta PR interval vs baseline (ms)
1 h 7.4 ± 29.9 2.3 ± 22.4 0.290
24 h 4.4 ± 19.7 3.5 ± 28.9 0.787
48 h 2.2 ± 19.9 19.8 ± 18.7 0.016
120 h 2.1 ± 20.9 33.7 ± 22.0 b0.001
1 month 1.9. ± 17.9 21.0 ± 10.6 0.021
Delta QRS duration vs baseline (ms)
1 h 11.8 ± 25.0 16.3 ± 26.5 0.591
24 h 6.7 ± 21.5 17.0 ± 26.9 0.061
48 h 7.7 ± 30.2 15.4 ± 23.2 0.384
120 h 7.7 ± 19.4 11.5 ± 25.8 0.981
1 month 4.9 ± 16.5 12.1 ± 28.3 0.281
New-onset LBBB (percentage)
1 h 15.4% 26.9% 0.110
24 h 18.5% 30.8% 0.120
48 h 18.5% 30.8% 0.120
120 h 15.4% 30.8% 0.259
1 month 12.3% 26.9% 0.086
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istics were comparable between the BEV and SEV groups.
Time course of changes in PR interval after BEV and SEV TAVR
In BEV patients, the PR interval did not increase significantly after
TAVR (PRBaseline 186 ± 34 ms, PR1hr 196 ± 35 ms, PR24hrs 191 ±
41 ms, PR48hrs 186 ± 43 ms and PR120hrs 187 ± 38 ms; p N 0.05 for all
when compared to baseline) (Fig. 1, panel A, green). The number of
BEV patients with PR prolongation N10 ms was 41.7% at 1 h, 34.1% at
24 h, 31.5% at 48 h and 32.0% at 120 h.
In SEV patients, the PR interval remained stable within the first 24 h
after TAVR implant (PRBaseline 172 ± 30 ms vs PR1hr 171 ± 29 ms and
PR24hrs 175 ± 32 ms; p N 0.05 for both when compared to baseline).
However, at 48 h a significant PR prolongation occurred (PR48hrs
197 ± 25 ms, p= 0.034 compared to PRBaseline) (Fig. 1, panel A, blue).
PR prolongation continued and peaked at 120 h (PR120hrs 205 ±
27 ms; p= 0.016 compared to PRBaseline). The number of SEV patients
with PR prolongation N10 ms was 33.8% at 1 h, 35.7% at 24 h, 63.3% at
48 h and 78.2% at 120 h.
Of interest, 1 month after TAVR the PR interval remained stable in
BEV patients (PR120hrs 187 ± 38 ms vs PR1month 184 ± 39 ms; p =
NS) and decreased again in SEV patients (PR120hrs 205 ± 27 ms vs
PR1month 194 ± 20ms; p=0.055). Only in SEV patients the PR interval
remained significantly increased compared to baseline (PRBaseline 172±
30 ms vs PR1month 194 ± 20 ms; P= 0.022).
When comparing PR prolongation between both groups, significant
differences in PR prolongation between BEV and SEV patients occurred
only from 48 h on and remained up till 1 month (Table 2).Fig. 1. Time course of ECG changes and conduction disorders after BEV and SEV TAVR. Panel A: S
patients. Panel B: In BEV patients, no significant differences in QRS duration could be observe
remained stable in further follow-up. Panel C: Both in BEV and SEV patients, all new-onset L
patients and 12.5% of SEV patients. No significant differences of new-onset LBBB incidence at d
patients required PPMI beyond 24 h with a significant higher rate in SEV (15.3%) vs BEV (
permanent pacemaker implantation; AF: atrial fibrillation; LBBB: left bundle branch block.Time course of changes in QRS duration after BEV and SEV TAVR
In BEV patients, a trend towards QRS widening was seen at 1 h post
TAVR when compared to baseline (QRSBaseline 108 ± 24.ms vs QRS1hr
118 ± 29 ms; p = 0.056). However, during further admission QRSDEV patients reveal more pronounced and delayed PR prolongation compared to BEV TAVR
d. In SEV patients, there was a significant and immediate increase in QRS duration which
BBB developed within first 24 h. After one month there was a resolution in 33.3% of BEV
ifferent time-intervals. Panel D: Time distribution of indication for PPMI. Overall, 5.4% of
1.5%) (p = .008). BEV: balloon expandable valve; SEV: self-expandable valve; PPMI:
Table 3
Comparison of demographic and clinical patient characteristics and procedural character-
istics in BEV and SEV patients with and without need for PPMI. PPMI = permanent pace-
maker implantation; BEV = balloon expandable valve; SEV = self-expandable valve;
BSA=body surface area; STSPROM=Society of Thoracic Surgeons Predicted Risk ofMor-
tality; NCC= non coronary cusp; LCC = left coronary cusp.
PPMI No PPMI P-value
Patient characteristics
Female (%) BEV 3.4% 59.6% 0.159
SEV 54.5% 46.7% 0.691
BSA (m2) BEV 1.9 ± 0.2 1.8 ± 0.2 0.436
SEV 1.8 ± 0.2 7.8 ± 0.2 0.878
Diabetes mellitus (%) BEV 12.5% 26.9% 0.545
SEV 36.4% 33.3% 0.873
Ischaemic heart disease (%) BEV 25.0% 40.4% 0.159
SEV 54.5% 40.0% 0.462
Atrial fibrillation (%) BEV 36.4% 36.5% 0.991
SEV 54.5% 26.7% 0.149
STSPROM BEV 5.3 [3.4–18.6] 4.7 [3.4–7.1] 0.699
SEV 4.2 [3.5–4.8] 4.5 [3.4–9.9] 0.507
Euroscore II BEV 6.3 [4.1–10.2] 4.6 [2.8–6.9] 0.397
SEV 7.7 [2.2–18.2] 8.2 [2.3–15.8] 1.000
Procedural characteristics
Predilation (%) BEV 45.5% 53.8% 0.613
SEV 54.5% 26.7% 0.149
Depth of implant at NCC BEV 6.3 ± 3.1 5.6 ± 2.2 0.462
SEV 6.9 ± 3.7 6.9 ± 2.7 0.950
Depth of implant at LCC BEV 6.8 ± 3.6 5.4 ± 1.8 0.331
SEV 8.7 ± 3.6 9.2 ± 2.7 0.245
Diameter of valve prosthesis BEV 25.7 ± 2.6 24.9 ± 2.6 0.336
SEV 28.4 ± 4.1 27.5 ± 3.0 0.468
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(QRS24hrs 116 ± 30 ms, QRS48hrs 116 ± 31 ms, QRS120hrs 118 ± 29 ms,
p value N0.05 for all compared to baseline) (Fig. 1, panel B, green). The
number of BEV patients with QRSD-prolongation N20 ms was 21.3% at
1 h, 18.1% at 24 h, 19.6% at 48 h and 20.3% at 120 h.
In SEV patients, the QRSD increased significantly immediately after
TAVR (QRSBaseline 104 ± 25 ms vs QRS1hr 121 ± 27 ms; P = 0.009)
and remained significantly increased at further follow up (QRS24hrs
119±29ms; p=0.031, QRS48hrs 117±31ms; p=0.017 andQRS120hrs
116 ± 29 ms; p= 0.012, all p-values for comparison with QRSBaseline)
(Fig. 1, panel B, blue). The number of SEV patients with QRSD-
prolongation N20 ms was 28.6% at 1 h, 30% at 24 h, 27.8% at 48 h and
28.6% at 120 h.
Time course of new left bundle branch block after TAVR
Overall, new-onset LBBB was seen in 18.5% of patients with BEV
(n= 12) and 30.8% of patients with SEV (n= 8) (p=0.120). In all pa-
tients (both BEV and SEV) who developed LBBB, LBBB occurred within
the 24 first hours after TAVR and in the majority of patients within the
first hour after TAVR (83.3% for BEV and 87.5% for SEV, p = 0.065)
(Fig. 1, Panel C). In BEV patients with new-onset LBBB, 33.3% (n = 4)
showed LBBB resolution at 1 month compared to 12.5% resolution in
SEV patients (n = 1) at 1 month (p = 0.292) (Fig. 1, Panel C). There
were no significant differences in prevalence of new-onset LBBB
among BEV and SEV patients at the different timing intervals (Table 2).
Permanent pacemaker indication and predictors
After TAVR and before discharge, 9.2% (n= 6) of BEV patients and
30.7% (n = 8) of SEV patients required PPMI (p = 0.003). In BEV pa-
tients who needed PPMI, 66.7% (n = 4) of patients had an indication
for PPMI within 1 h after TAVR, 16.7% (n = 1) between 1 h and 24 h
and 16.7% (n = 1) after 48 h (Fig. 1, Panel D, green). In SEV patients
who needed PPMI, 37.5% (n = 3) of patients had an indication for
PPMI within 1 h, 12.5% (n = 1) between 1 and 24 h, 12.5% (n = 1) be-
tween 24 and 48 h and an additional 37.5% (n = 3) after 48 h (Fig. 1,
Panel D, blue). Need for PPMI after 24 h occurred in 5.4% (n=5) of pa-
tients with a significant higher prevalence in SEV patients (15.3%) vs
BEV patients (1.5%) (p= 0.008). There were no significant differences
in baselinedemographic and clinical patient characteristics between pa-
tients with and without PPMI (Table 3).
Discussion
Main findings
To the best of our knowledge this is the first study assessing the de-
tailed time course of new onset ECG changes and conduction disorders
according to the TAVR valve design. Our results show that PR prolonga-
tion is more pronounced and has a delayed time course in SEV TAVR
compared to BEV TAVR. In contrast, widening of QRSD and occurrence
of new-onset LBBB occurs immediately after TAVR implant in both
BEV and SEV TAVR. In our study, the need for permanent pacemaker
after 24 h occurred more frequently in SEV patients compared to BEV
TAVR patients.
PR prolongation post TAVR
The importance of PR interval prolongation following TAVR has re-
cently gained interest as a predictor of late high grade AV-block requir-
ing PPMI and long-term cardiac pacing dependency [8,14]. This could be
explained by the fact that post-procedural PR interval prolongation
might represent a significant damage to the conduction system, either
to the AV-node or to the conduction system below the bundle of His.
Akin et al. demonstrated that 82% of patients with a prolongation ofthe PR interval after TAVR had a new acquired prolongation of the HV
(His-bundle to first ventricular activation) interval [15]. In addition, ob-
servational studies in a healthy cohort showed that people with a
prolonged PR interval have a 3-fold increased risk for PPMI irrespective
of age and QRS length [16]. Our findings are in linewith earlier data of a
small study in 33 patients with first generation SEV that demonstrated a
continued PR interval prolongation for a number of days after TAVR and
only a partial recovery later on [17].
Our study shows that, while BEVpatients developednoPRprolonga-
tion, PR interval significantly prolonged in SEV patients after 24 h and
peaked at 120 h. Our observation of delayed PR prolongation in SEV pa-
tients implies that early ECG evaluation within the first 24 to 48 h after
SEV TAVRmight not adequately detect the injury to the conduction sys-
tem, as represented by PR prolongation. Besides direct trauma by the
delivery system advanced on a stiff guidewire or compression of the
conduction systemby either balloon dilatation or stent frame, also path-
ophysiological mechanisms such as edema, inflammation and fibrosis
might continue over several days before reaching full effect on the con-
duction system. Furthermore, continued injury caused by persisting ra-
dial force of the self-expanding nitinol frame in SEV might also explain
both the prolonged time course and the lower resolution rates of PR
prolongation in SEV TAVR patients [18]. As the atrioventricular (AV)
conduction system runs below the NCC, valve implant depth measured
from the NCC is considered a major determinant for impaired AV con-
duction [19]. In our study, implant depth measured from the NCC was
comparable between SEV and BEV and cannot account for themore pro-
nounced and delayed PR prolongation in SEV patients.
QRS changes after BEV and SEV TAVR
We found no significant increase in QRSD in BEV TAVR patients. In
SEV TAVR patients however, therewas an immediate and significant in-
crease in QRSD. These findings are in line with previous observations in
45 patients implanted with the Medtronic CoreValve and a second
larger study in 291 patients with Medtronic Corevalve, Edwards Sapien
3, Edwards Sapien XT and Boston Scientific Lotus valves [20,21]. New-
onset LBBB occurs more frequent in the SEV patients compared to BEV
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numerically higher, but did not reach statistical significance. As for QRS
duration, the occurrence of LBBB occurred fast: all patients with new-
onset LBBB in our study developed this within 24 h after TAVR in both
BEV and SEV patients. In another study by Houthuizen et al. with clearly
higher incidence of new-onset LBBB (53.8% in SEV and 21.7% in BEV)
new-onset LBBB occurred within 24 h in 85.7% of patients [18]. In our
study, after one month there was a resolution in some patients and
persisting of new-onset LBBB in 12.3% of BEV patients and 26.9% of
SEV patients, which is comparable to the 35% of resolution observed in
a previous study and which emphasizes the lower recuperation rate in
SEV [18]. We did not observe any additional new-onset LBBB between
discharge and one month of follow-up.Pacemaker implantation after TAVR
The rates for PPMI in our studywere significantly higher in SEV com-
pared to BEV TAVR patients and are in line with previous studies [5].
Also, our rates for pacemaker implantation beyond 24 h are in line
with previous studies when taking into account the type of valve design
[7,9,21]. Some recent studies examined post TAVR ECG changes as pre-
dictors of delayed AVB and to guide PPMI [7–10]. However, there is no
agreement among these studies, neither on which ECG parameter (PR
interval, QRSD or both) should be evaluated, nor on the timing when
the ECG should be evaluated. In the study of Toggweiler and Jorgensen
both PR and QRS durations were taken into account, whereas Mangieri
only found post-TAVR PR prolongation associated with delayed ad-
vanced conduction disturbances and not QRS duration. However, both
studies included SEV and BEV patients but did not specify ECG predic-
tors according to valve design. One study of Takahashi et al. was con-
ducted solely in SEV patients and only found QRS duration N120 ms
post TAVR predictive for late PPMI [10]. The aforementioned studies
also differ in timing of ECG evaluation. Interestingly, all studies which
found widening in QRS duration to be predictive for PPMI, evaluated
the ECG immediately post TAVR [7,9,10].Whereas the study ofMangieri
which found PR prolongation to predict late AVB, evaluated the ECG at
48 h post TAVR [8]. These observations are in line with our findings,
showing that QRS prolongation and LBBB development occurs immedi-
ate after TAVR, whereas PR prolongation shows a more delayed time
course, especially in SEV patients. As there is growing evidence that
PR prolongation after TAVR is associated with an increased risk for late
AVB, independently of QRS width, it seems careful to keep SEV patients
at least 48 h on heart rhythm monitoring to evaluate PR prolongation.
Future studies should not only evaluate whether QRS or PR prolonga-
tion should be taken into account, but also address themost appropriate
timing for ECG evaluation according to each valve design. Such studies
might also provide us further insights in the mechanism of conduction
disorders for each valve design and improve valve design in order to re-
duce the rate of these conduction complications.Limitations
This was a single-center study with relatively small sample size.
However, differences in timing of PR prolongation and QRS widening
reached statistical significance for comparison between BEV and SEV
TAVR patients. Larger prospective studies are necessary to define the
best timing of evaluating ECG changes to decide whether PPMI post
TAVR is indicated to avoid late AVB. Long-term outcomes of our pa-
tients, such as death, cardiovascular death and cardiovascular events
during the follow-up period were not evaluated. Hence, we did not de-
termine the relation between different conduction dynamics and over-
all prognosis. The study had a long inclusion period, which may have
caused a bias as some patients were treated with older types of valves
which are nowadays less used in contemporary clinical practice.Conclusion
New onset ECG changes and conduction abnormalities after TAVR
reveal different time patterns in relation to the valve design. SEV TAVR
patients show more pronounced and delayed impairment in atrioven-
tricular conduction compared to BEV TAVRpatients. However, QRSwid-
ening occurs in both SEV and BEV patients immediate after TAVR. PPMI
requirement beyond 24 h was significantly higher in SEV patients. Our
findings suggest that SEV TAVR patients require at least 48 h telemetry
after TAVR to adequately assess PR prolongation.
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